| Literature DB >> 26366128 |
Daniela Reischl1, Christian Röthel2, Paul Christian2, Eva Roblegg1, Heike M A Ehmann3, Ingo Salzmann4, Oliver Werzer1.
Abstract
Polymorphism and morphology can represent key factors tremendously limiting the bioavailability of active pharmaceutical ingredients (API), in particular, due to solubility issues. Within this work, the generation of a yet unknown surface-induced polymorph (SIP) of the model drug, 5,5-diphenylimidazolidin-2,4-dion (phenytoin), is demonstrated in thin films through altering the crystallization kinetics and the solvent type. Atomic force microscopy points toward the presence of large single-crystalline domains of the SIP, which is in contrast to samples comprising solely the bulk phase, where extended dendritic phenytoin networks are observed. Grazing incidence X-ray diffraction reveals unit cell dimensions of the SIP significantly different from those of the known bulk crystal structure of phenytoin. Moreover, the aqueous dissolution performance of the new polymorph is benchmarked against a pure bulk phase reference sample. Our results demonstrate that the SIP exhibits markedly advantageous drug release performance in terms of dissolution time. These findings suggest that thin-film growth of pharmaceutical systems in general should be explored, where poor aqueous dissolution represents a key limiting factor in pharmaceutical applications, and illustrate the experimental pathway for determining the physical properties of a pharmaceutically relevant SIP.Entities:
Year: 2015 PMID: 26366128 PMCID: PMC4561386 DOI: 10.1021/acs.cgd.5b01002
Source DB: PubMed Journal: Cryst Growth Des ISSN: 1528-7483 Impact factor: 4.076
Figure 1Atomic force microscopy height images of a phenytoin sample prepared from EtOH solution (a) or from THF solution (b). A reflection mode optical microscopy image taken under crossed polarizers of the THF sample is shown in (c). The dotted lines indicate the grain boundaries of the surface-induced phase, and arrows indicate the position of trenches in between two common areas.
Figure 2Specular X-ray diffraction scans of phenytoin samples prepared from THF (bottom) and EtOH (center) solutions compared to a calculated spectra of an ideal powder of the bulk polymorph (top).
Figure 3Top: Experimental grazing incidence X-ray diffraction data of the THF sample containing randomly distributed bulk-phase crystallites (rings) and sharp spots originating from the SIP. Bottom: Corresponding indexation of the spots on the basis of the SIP unit cell parameters derived within this work (see text).
Figure 4In situ temperature-dependent specular X-ray diffraction scans of a phenytoin sample established from THF solution (a) and the extracted peak intensities of the two different phases normalized to the initial value (b). A common abscissa is used for comparability.
Figure 5Phenytoin release as a function of time for two samples represented on a linear scale for a short time period (a) and the entire experimental data on a double logarithmic scale (b).